STP-707 is under clinical development by Sirnaomics and currently in Phase I for Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Squamous Cell Carcinoma have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how STP-707’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

STP-707 overview

STP-707 is under development for the treatment of cholangiocarcinoma, hepatocellular carcinoma, primary sclerosing cholangitis, liver fibrosis, solid tumors, lung fibrosis, non-alcoholic steatohepatitis (NASH), metastatic cutaneous squamous cell carcinoma, liver metastases and non-small cell lung cancer. It is a systemic formulation of STP-705. It is administered intravenously and inhalational. The drug candidate acts by targeting transforming growth factor beta 1 (TGF beta 1) and cyclooxygenase-2. It is developed based on RNAi technology.

Sirnaomics overview

Sirnaomics, is a healthcare service provider that discovers and develops therapeutics. The company’s products portfolio includes siRNA and niRNA. It offers product development, preclinical programs, clinical development services, and others. Sirnaomics provides its products for therapeutic programs such as lung cancer, breast cancer, organ transplantation, skin hypertrophic scars, colorectal cancer, influenza A, HPV and cervical cancer, ocular neo-vascularization, spinal cord injury, EBOLA infection, and giloblastoma, among others. The company also provides active pharmaceutical ingredients as therapeutic agents for treatment of various critical human diseases. It has its presence in the US and China. the company is headquartered in Gaithersburg, Maryland, the US.

For a complete picture of STP-707’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.